Research
Hormonal
Semaglutide (GLP-1 receptor agonist) significantly reduces major adverse cardiovascular events (MACE) in high-risk patients with type 2 diabetes and established cardiovascular disease.
If you have type 2 diabetes and existing heart disease or high risk, ask your doctor about semaglutide. It is a once-weekly injection that has been proven to significantly reduce the risk of heart attacks, strokes, and cardiovascular death.
StrongSupportsHIGH confidence
The SUSTAIN-6 trial demonstrated a 26% MACE reduction (HR 0.74; 95% CI: 0.58–0.95; p = 0.02) in high CV-risk patients with T2D using semaglutide (0.5 or 1.0 mg weekly).
Why this rating
Based on large, randomized controlled trials (SUSTAIN-6) with statistically significant results.
Source
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
Richard J. MacIsaac · Future Cardiology · 2025
narrative_reviewCited 11×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →